ABT vs BSX vs JNJ Stock Comparison

Abbott Laboratories, Boston Scientific and Johnson & Johnson Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$186.70B
P/E
39.7x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
2 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$63.42B
P/E
18.1x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
4 wins
JNJ Johnson & Johnson
$286.11 +12.7% 1M +46.5% 1Y
Market cap
$682.35B
P/E
42.4x
Revenue (TTM)
$99.34B
Div. yield
0.02%
Pharmaceuticals Healthcare
6 wins

Head to Head

12 decided of 12

Johnson & Johnson leads on 6 of the 12 questions below (Johnson & Johnson 6, Boston Scientific 4, Abbott Laboratories 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTBSXJNJLeader
Larger companyMarket capitalisation $186.70B $63.42B $682.35B JNJ
Cheaper on earningsLower P/E, profitable companies only 39.7x 18.1x 42.4x BSX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 14.5x 26.7x BSX
Faster revenue growthRevenue growth, trailing twelve months +10.0% +8.9% +7.8% ABT
More profitableNet margin, trailing twelve months 9.7% 16.6% 16.2% BSX
Better return on capitalReturn on invested capital 5.7% 9.9% 17.6% JNJ
Less leveragedLower net debt / EBITDA 2.5x 2.1x 0.8x JNJ
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.02% ABT
Better 1-year returnPrice return, last 12 months -16.0% -57.8% +46.5% JNJ
Better 5-year returnAnnualised price return, 5 years -3.3%/yr +1.1%/yr +11.6%/yr JNJ
Less volatileAnnualised volatility, 1 year 28.5% 41.5% 21.2% JNJ
Higher overall scoreMean of the five percentile scores vs peers 56/100 68/100 65/100 BSX

Percentile Scorecard

ABTBSXJNJ

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTBSXJNJ
Valuation 74 #65 of 243 87 #33 of 243 84 #104 of 660
Growth 26 #168 of 228 68 #73 of 228 34 #410 of 619
Profitability 82 #41 of 222 91 #20 of 222 94 #39 of 595
Financial Health 33 #167 of 248 43 #142 of 248 39 #416 of 683
Shareholder Returns 65 #56 of 158 48 #82 of 158 73 #123 of 459
Overall 56 68 65
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics
  • JNJ ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTBSXJNJSPY
1 month +5.4%+3.1%+12.7% -2.0%
3 months -2.4%-14.5%+9.9% -2.8%
6 months +28.5%-15.8%+26.2% +2.0%
Year to date -13.4%-53.5%+38.3% +10.6%
1 year -16.0%-57.8%+46.5% +12.2%
3 years +11.8%-17.9%+93.8% +68.1%
3 years, per year +3.8%-6.4%+24.7% +18.9%
5 years -15.5%+5.4%+73.4% +61.4%
5 years, per year -3.3%+1.1%+11.6% +10.1%
10 years +170.4%+106.2%+141.5% +248.5%
10 years, per year +10.5%+7.5%+9.2% +13.3%

Risk

MeasureABTBSXJNJSPY
Volatility, 1Y 28.5%41.5%21.2% 13.6%
Downside volatility, 1Y 27.8%47.7%20.1% 13.9%
Beta vs S&P 500, 1Y 0.070.26-0.09 1.00
Return / volatility, 1Y -0.56-1.392.19 0.90
Max drawdown, 5Y -41.6%-61.6%-23.6% -25.4%
From 52-week high -16.9%-57.8%0.0% -3.2%
52-week high $130.59$104.98$286.11 $779.14
52-week low $82.56$41.57$195.25 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTBSXJNJ
P/E now vs peer median 40.0xmedian 26.5x 18.3xmedian 26.5x 42.8xmedian 17.0x
P/S now vs peer median 3.9xmedian 2.7x 3.1xmedian 2.7x 6.9xmedian 8.4x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 14.1xmedian 18.4x 21.5xmedian 14.6x
P/FCF now vs peer median 27.8xmedian 25.4x 19.3xmedian 25.4x 33.5xmedian 19.0x
P/B now vs peer median 3.6xmedian 2.5x 2.5xmedian 2.5x 8.4xmedian 2.0x
PEG now vs peer median -13.92median 0.98 0.42median 0.98 -1.42median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTBSXJNJ
Revenue $48.23B $21.07B $99.34B
Gross profit $27.46B $14.57B $67.11B
Operating income $6.65B $3.93B $25.19B
Net income $4.70B $3.49B $16.10B
Free cash flow $6.76B $3.33B $20.59B
R&D $3.31B $2.16B $16.08B
EPS (diluted) $2.70 $2.41 $6.57
Cash & equivalents $4.05B $609.00M $16.91B
Total debt $31.16B $11.95B $44.65B
Shares (diluted) 1.74B 1.45B 2.45B
Enterprise value $160.56B $58.85B $602.21B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTBSXJNJ
P/E 40.0x 18.3x 42.8x
P/FCF 27.8x 19.3x 33.5x
P/Operating cash flow 21.2x 15.2x 26.3x
P/S 3.9x 3.1x 6.9x
P/B 3.6x 2.5x 8.4x
P/Tangible book 5.9x 3.4x 19.7x
EV/EBITDA 20.3x 14.1x 21.5x
EV/EBIT 32.3x 19.2x 28.4x
EV/Revenue 4.5x 3.6x 7.2x
EV/FCF 31.8x 22.7x 34.8x
EV/Operating cash flow 24.3x 17.9x 27.4x
PEG (3Y EPS CAGR) -13.92 0.42 -1.42

Growth

14 metrics
MetricABTBSXJNJ
Revenue growth (1Y) 10.0% 8.9% 7.8%
Revenue CAGR (3Y) 6.5% 15.3% -14.5%
Gross profit growth (1Y) 12.1% 9.8% 7.0%
Gross profit CAGR (3Y) 7.8% 15.1% -12.3%
Operating income growth (1Y) -13.8% 13.5% 7.4%
Operating income CAGR (3Y) 3.5% 22.1% -12.8%
Net income growth (1Y) -66.4% 25.5% -35.9%
Net income CAGR (3Y) -3.1% 41.7% -31.0%
EPS growth (1Y) -66.1% 29.2% -36.4%
EPS CAGR (3Y) -2.9% 44.0% -30.1%
Operating cash flow growth (1Y) -2.9% -8.5% 8.1%
Operating cash flow CAGR (3Y) 10.6% 21.6% 11.4%
Free cash flow growth (1Y) -2.3% -12.9% 5.1%
Free cash flow CAGR (3Y) 14.6% 25.2% 8.8%

Profitability

14 metrics
MetricABTBSXJNJ
Gross margin 56.9% 69.1% 67.6%
EBITDA margin 21.9% 25.5% 33.5%
Operating margin 13.8% 18.7% 25.4%
Pretax margin 13.6% 17.3% 17.9%
Net margin 9.7% 16.6% 16.2%
FCF margin 14.0% 15.8% 20.7%
Operating cash flow margin 18.4% 20.1% 26.3%
Return on equity 9.1% 13.7% 19.3%
Return on assets 4.3% 7.7% 8.1%
Return on invested capital 5.7% 9.9% 17.6%
Return on capital employed 7.2% 10.0% 17.5%
Asset turnover 0.4x 0.5x 0.5x
Cash conversion (OCF / net income) 1.9x 1.2x 1.6x
Stock comp / revenue 1.5% 1.5% 1.4%

Financial Health

11 metrics
MetricABTBSXJNJ
Debt / assets 28.8% 26.3% 22.6%
Debt / equity 0.6x 0.5x 0.5x
Net debt / EBITDA 2.5x 2.1x 0.8x
Debt / FCF 4.6x 3.6x 2.2x
Liabilities / assets 52.3% 43.1% 58.7%
Equity / assets 47.7% 56.9% 41.3%
Interest coverage 6.7x 10.5x 25.6x
Current ratio 1.5x 1.4x 1.0x
Quick ratio 0.8x 0.6x 0.7x
Cash ratio 0.3x 0.1x 0.3x
Altman Z-score 3.36 3.03 5.69

Shareholder Returns

7 metrics
MetricABTBSXJNJ
Dividend yield 2.3% – 1.8%
Net buyback yield 0.7% -0.3% 0.6%
Shareholder yield 3.0% -0.3% 2.4%
Payout ratio (earnings) 92.0% – 79.0%
Payout ratio (FCF) 64.0% – 61.8%
Dividend growth (1Y) 6.9% – 3.9%
Dividend CAGR (3Y) 7.4% – 2.8%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTBSXJNJ
Forward P/E 19.1xFY2026 14.5xFY2026 26.7xFY2026
EPS, next fiscal year $5.69FY2026 $3.06FY2026 $10.72FY2026
EPS growth, next FY +10.5%FY2026 0.0%FY2026 -0.6%FY2026
EPS growth, the year after +10.2% +8.2% +5.8%
Revenue, next fiscal year $52.99BFY2026 $20.48BFY2026 $106.55BFY2026
Revenue growth, next FY +19.5%FY2026 +2.1%FY2026 +13.1%FY2026
Revenue growth, the year after -2.3% -4.0% +6.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTBSXJNJ
Held by institutions 79.2% 90.5% 74.7%
Institutions holding 2,983 1,484 4,699
Change in shares held, QoQ +0.3% -0.7% +1.8%
Institutions buying 1,261 738 2,297
Institutions selling 1,379 612 1,899
Buyers to sellers 0.91 1.21 1.21

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTBSXJNJ
ABT 1.00 0.40 0.29
BSX 0.40 1.00 0.16
JNJ 0.29 0.16 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, BSX and JNJ?

Johnson & Johnson (JNJ) is the largest by market capitalisation: Abbott Laboratories (ABT) $186.70B, Boston Scientific (BSX) $63.42B, Johnson & Johnson (JNJ) $682.35B.

Which stock is cheaper, ABT, BSX and JNJ?

Boston Scientific (BSX) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 39.7x, Boston Scientific (BSX) 18.1x, Johnson & Johnson (JNJ) 42.4x). On next year's consensus earnings, Boston Scientific (BSX) is cheapest (Abbott Laboratories (ABT) 19.1x, Boston Scientific (BSX) 14.5x, Johnson & Johnson (JNJ) 26.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Boston Scientific (BSX) +8.9%, Johnson & Johnson (JNJ) +7.8%.

Which company is more profitable?

Boston Scientific (BSX) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Boston Scientific (BSX) 16.6%, Johnson & Johnson (JNJ) 16.2%). On return on invested capital, Johnson & Johnson (JNJ) leads (Abbott Laboratories (ABT) 5.7%, Boston Scientific (BSX) 9.9%, Johnson & Johnson (JNJ) 17.6%).

Which stock has performed better?

Over the past year Johnson & Johnson (JNJ) returned the most: Abbott Laboratories (ABT) -16.0%, Boston Scientific (BSX) -57.8%, Johnson & Johnson (JNJ) +46.5%. Over five years, Johnson & Johnson (JNJ) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Boston Scientific (BSX) +1.1%/yr, Johnson & Johnson (JNJ) +11.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Abbott Laboratories (ABT) has the highest dividend yield: Abbott Laboratories (ABT) 0.02%, Boston Scientific (BSX) 0.00%, Johnson & Johnson (JNJ) 0.02%. Boston Scientific (BSX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Johnson & Johnson (JNJ) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Boston Scientific (BSX) 41.5%, Johnson & Johnson (JNJ) 21.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, BSX and JNJ?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Johnson & Johnson (JNJ) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.